When will Dynavax Technologies Corporation report its third quarter 2024 financial results?

Dynavax Technologies Corporation will report its third quarter 2024 financial results on November 7, 2024, after the U.S. financial markets close.

What time is Dynavax's conference call scheduled?

The conference call and live audio webcast will take place on November 7, 2024, at 4:30 p.m. ET / 1:30 p.m. PT.

Where can investors access the live audio webcast of the conference call?

The live audio webcast can be accessed through the 'Events & Presentations' page on Dynavax's Investors section of their website.

What is required for participants to join the conference call?

Participants need to register via a caller registration link provided in the announcement to dial into the conference call.

What commercial products does Dynavax currently have?

Dynavax has two commercial products: HEPLISAV-B, a Hepatitis B vaccine, and CpG 1018 adjuvant utilized in various COVID-19 vaccines.

Dynavax to Report Third Quarter 2024 Financial Results and Host Conference Call on November 7, 2024

10/24/24 4:10:00 PM ET

$DVAX

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $DVAX alert in real time by email

EMERYVILLE, Calif., Oct. 24, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report third quarter 2024 financial results on Thursday, November 7, 2024, after the U.S. financial markets close.

Dynavax will host a conference call and live audio webcast on Thursday, November 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT.

The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations. A replay of the webcast will be available for 30 days following the live event.

To dial into the call, participants will need to register for the call using the caller registration link. It is recommended that participants dial into the conference call or log into the webcast approximately 10 minutes prior to the call.

About Dynavax

Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and Great Britain for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant with adjuvanted vaccine clinical programs for shingles and Tdap, and through global collaborations, currently focused on adjuvanted vaccines for COVID-19, plague, seasonal influenza and universal influenza. For more information about our marketed products and development pipeline, visit www.dynavax.com and follow Dynavax on LinkedIn and Twitter.

For Investors/Media:

Paul Cox

[email protected]

510-665-0499

Nicole Arndt

[email protected]

510-665-7264

View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-report-third-quarter-2024-financial-results-and-host-conference-call-on-november-7-2024-302286555.html

SOURCE Dynavax Technologies

Get the next $DVAX alert in real time by email

Recent Analyst Ratings for

$DVAX

Date	Price Target	Rating	Analyst
2/1/2024	$20.00	Neutral	Goldman
9/27/2022	$22.00	Mkt Outperform	JMP Securities
1/6/2022	$38.00	Buy	Goldman
12/29/2021	$23.00 → $28.00	Buy	HC Wainwright & Co.
8/31/2021	$20.00 → $23.00	Buy	HC Wainwright & Co.
8/6/2021	$19.00	Buy	Goldman Sachs
8/5/2021	$16.00 → $20.00	Buy	HC Wainwright & Co.

More analyst ratings

Dynavax to Report Third Quarter 2024 Financial Results and Host Conference Call on November 7, 2024

Chat with this insight

Q&A

When will Dynavax Technologies Corporation report its third quarter 2024 financial results?

What time is Dynavax's conference call scheduled?

Where can investors access the live audio webcast of the conference call?

What is required for participants to join the conference call?

What commercial products does Dynavax currently have?

Recent Analyst Ratings for $DVAX

$DVAX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

New insider Deep Track Biotechnology Master Fund, Ltd. claimed ownership of 17,791,486 shares (SEC Form 3)

Cano Francis sold $43,127 worth of shares (3,615 units at $11.93), decreasing direct ownership by 9% to 36,905 units (SEC Form 4)

Myers Scott Dunseth was granted 5,357 shares, increasing direct ownership by 27% to 25,446 units (SEC Form 4)

$DVAX SEC Filings

SEC Form 8-A12B filed by Dynavax Technologies Corporation

Dynavax Technologies Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure

SEC Form S-8 filed by Dynavax Technologies Corporation

$DVAX Financials

Live finance-specific insights

Dynavax Adopts Limited-Duration Stockholder Rights Plan